Dobutamine as selective beta 1-adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization

• Published in: Journal of applied physiology (1985) 1999-09, Vol.87 (3), p.977-981
• Main Authors: Schiffelers, S. L. H, van Harmelen, V. J. A, de Grauw, H. A. J, Saris, W. H. M, van Baak, M. A
• Format: Article
• Language: English
• ISSN: 8750-7587; 1522-1601
• DOI: 10.1152/jappl.1999.87.3.977

Nutrition Toxicology and Environment Research Institute Maastricht, Department of Human Biology, Maastricht University, 6200 MD Maastricht, The Netherlands The use of dobutamine as selective 1 -adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization was investigated in 20 men. At 2.5, 5, and 10 µg · kg 1 · min 1 , dobutamine induced significant increases in energy expenditure, lipid oxidation, and lipolysis. The 1 -adrenoceptor antagonist atenolol (bolus: 42.5 µg/kg, infusion: 1.02 µg · kg 1 · min 1 ) blocked all dobutamine-induced effects on thermogenesis and lipid utilization. All parameters remained at levels comparable to those during saline infusion. The dose of atenolol used did not inhibit 2 -adrenoceptor-specific changes in energy expenditure, lipid oxidation, and lipolysis during salbutamol infusion (85   ng · kg 1 · min 1 ). This indicates that atenolol was specific for 1 -adrenoceptors and did not camouflage concomitant 2 -adrenoceptor stimulation during dobutamine infusion. Therefore, we conclude that dobutamine can be used as a selective 1 -adrenoceptor agonist at dosages 10 µg · kg 1 · min 1 in in vivo studies on human thermogenesis and lipid utilization. atenolol; salbutamol; lipid oxidation; lipolysis